Hypertrophic Cardiomyopathy: Current Treatment and Future Options

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Hypertrophic cardiomyopathy (HCM) is a primary cardiac sarcomere disease with diverse genetic causes and clinical presentations.
• It affects patients across all age groups and is a leading cause of sudden cardiac death in young athletes.
• Despite therapeutic advances reducing overall mortality, risk stratification for sudden cardiac death in a subset of patients remains challenging.

Purpose of the Study:

• To provide a practical guide to updated recommendations for hypertrophic cardiomyopathy (HCM) management.
• To cover recent advancements in diagnosis, family screening, and clinical imaging for HCM.
• To address critical challenges in risk stratification and prognosis assessment for HCM patients.

Main Methods:

• Review of current literature and updated clinical guidelines for hypertrophic cardiomyopathy.
• Synthesis of information on genetic mutations, phenotypic expressions, and therapeutic options.
• Analysis of technological advancements in diagnosis and risk stratification tools.

Main Results:

• HCM exhibits significant heterogeneity, impacting patients of all ages.
• Mortality rates in HCM have decreased to 0.5% annually due to improved therapies and diagnostics.
• Despite progress, identifying patients at high risk for sudden cardiac death remains a critical unmet need.

Conclusions:

• Updated clinical guidelines are essential for the diagnosis, family screening, imaging, risk stratification, and management of HCM.
• Continued research into molecular defects and prognostic markers is crucial for personalized HCM care.
• Effective risk stratification strategies are paramount to prevent sudden cardiac death in susceptible HCM individuals.